Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well venetoclax and azacitidine work for the treatment of
acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of
cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Chemotherapy
drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving venetoclax and azacitidine after a stem cell transplant may help control high risk
leukemia and prevent it from coming back after the transplant.